Maybe they'll go the investment banking route and seek out someone to engage in a secondary offering?

My favorite short, Ziopharm....they engaged in a secondary that was led JP Morgan and included BMO and two or three other firms one of which was a company called Griffin. That was in early 2015.

I know that some fear the prospect of secondary offerings, but they can be extremely positive for a company's share price as Ziopharm bears out. In October of 2014 ZIOP's PPS was languishing, trading down near $2 per shares.

By the time the secondary was underway the PPS had climbed over $8 on its way to over $14. Ziopharm did a presentation at a JP Morgan healthcare conference, an analyst from BMO put out a report on them with a nice price target, Griffin's analyst...some guy named Markey, put a $21 target on the stock.

Ziopharm of course had something to get the retail crowd excited, they paid the MD Anderson Cancer Center $57.5 million in stock for a partnership deal and the CAR-T space they were getting into was hot.

Does Resverlogix have something that would get the retail crowd excited? I think they do....but unless or until there are parties engaged who stand to profit from a rising share price, I see us drifting.

Why would the real market players (investment bankers, analysts, promoters etc) tout an investment in RVX when there's no incentive for them to do it? There are companies out there playing the game, so those are the stocks that get the spotlight.

You guys know I've done a bit of acting....So why does the inferior actress get the lead role when there's another woman with superior talent? Maybe its because of services (cough) she's providing to the director? Could be....I've seen it happen first hand.